KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) EBITDA (2016 - 2025)

TherapeuticsMD's EBITDA history spans 16 years, with the latest figure at -$1.6 million for Q4 2025.

  • For Q4 2025, EBITDA fell 138.04% year-over-year to -$1.6 million; the TTM value through Dec 2025 reached -$4.0 million, up 30.38%, while the annual FY2025 figure was -$4.4 million, 28.17% up from the prior year.
  • EBITDA reached -$1.6 million in Q4 2025 per TXMD's latest filing, down from -$862000.0 in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $112.3 million in Q2 2022 to a low of -$49.0 million in Q1 2022.
  • Average EBITDA over 5 years is -$4.0 million, with a median of -$2.0 million recorded in 2023.
  • Peak YoY movement for EBITDA: soared 363.25% in 2022, then crashed 138.04% in 2025.
  • A 5-year view of EBITDA shows it stood at -$43.0 million in 2021, then soared by 280.87% to $77.7 million in 2022, then tumbled by 101.14% to -$883000.0 in 2023, then increased by 26.16% to -$652000.0 in 2024, then plummeted by 138.04% to -$1.6 million in 2025.
  • Per Business Quant, the three most recent readings for TXMD's EBITDA are -$1.6 million (Q4 2025), -$862000.0 (Q3 2025), and -$695000.0 (Q2 2025).